Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ogivri - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Ogivri

Approved

STANDARD

Ogivri

Biocon Biologics India Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: e839f90a32b6df07
Company: Biocon Biologics India Limited
Type: Standard

Approval Details

Approval Id: e839f90a32b6df07
Drug Approval Philippines Name: Ogivri
Product Name: Ogivri
Registration Number: BRP-120
Brand Name: Ogivri
Generic Name: Trastuzumab
Dosage Form: Powder for Concentrate for Solution for Infusion (IV)
Dosage Strength: 420 mg
Manufacturer: Biocon Biologics India Limited
Trader: Mylan Pharmaceuticals Private Limited
Importer: Viatris Pharmaceuticals, Inc.
Distributor: Viatris Pharmaceuticals, Inc.
Trader Detail Path: /organization/mylan-pharmaceuticals-private-limited
Issuance Date: 24 January 2023
Expiry Date: 24 January 2028
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

e839f90a32b6df07

Type

Standard

Back to Philippines FDA Approvals